Table 2. Univariate analysis of prognostic factors for disease-free survival and overall survival in 195 hepatocellular carcinoma patients.
| Variables | N | DFS | OS | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |||
| Gender (female/male) | 21/174 | 1.063 (0.597, 1.892) | 0.836 | 0.860 (0.298, 2.481) | 0.781 | |
| Age, years (≤50/>50) | 95/100 | 0.979 (0.685, 1.399) | 0.906 | 0.498 (0.229, 1.045) | 0.065 | |
| Cirrhosis (absent/present) | 69/126 | 1.065 (0.727, 1.561) | 0.746 | 0.958 (0.448, 2.051) | 0.912 | |
| Tumor diameter, cm (≤5/>5) | 113/82 | 2.096 (1.457, 3.016) | <0.001 | 2.558 (1.229, 5.325) | 0.012 | |
| Tumor number (single/multiple) | 147/48 | 2.051 (1.397, 3.012) | <0.001 | 1.110 (0.475, 2.595) | 0.810 | |
| Vascular invasion (absent/present) | 115/80 | 1.972 (1.374, 2.830) | <0.001 | 2.724 (1.302, 5.700) | 0.008 | |
| BCLC stage (0~A/B/C) | 98/77/20 | <0.001 | 0.017 | |||
| BCLC stage (0~A/B) | 1.863 (1.259, 2.757) | 0.002 | 1.995 (0.884, 4.502) | 0.096 | ||
| BCLC stage(0~A/C) | 3.968 (2.288, 6.879) | <0.001 | 4.305 (1.564,11.850) | 0.005 | ||
| Pathological differentiation (well/poor-moderate) | 26/169 | 1.941 (1.060, 3.554) | 0.032 | 3.109 (0.730, 13.240) | 0.125 | |
| Intraoperative blood transfusion (absent/present) | 99/96 | 1.468 (1.024, 2.105) | 0.037 | 1.186 (0.576, 2.439) | 0.643 | |
| AFP, ng/mL (≤400/>400) | 130/65 | 1.431 (0.988, 2.074) | 0.058 | 2.350 (1.146, 4.820) | 0.020 | |
| HBV-DNA, copies/mL (≤1,000/>1,000) | 94/101 | 1.309 (0.914, 1.874) | 0.142 | 2.295 (1.048, 5.027) | 0.038 | |
| Pre-NLR (≤2/>2) | 103/92 | 1.385 (0.969, 1.979) | 0.074 | 1.677 (0.813, 3.460) | 0.162 | |
| NLR (4–8 w) (≤2/>2) | 137/58 | 1.742 (1.193, 2.544) | 0.004 | 2.838 (1.379, 5.841) | 0.005 | |
| NLR (3–6 m) (≤2/>2) | 126/69 | 2.144 (1.494, 3.077) | <0.001 | 3.122 (1.500, 6.497) | 0.002 | |
| NLRc (4–8 w) (no change/≥25% increase/≥25% decrease) | 73/26/96 | 0.693 | 0.118 | |||
| NLRc (4–8 w) (no change/≥25% increase) | 1.251 (0.716, 2.186) | 0.432 | 2.615 (0.985, 6.944) | 0.054 | ||
| NLRc (4–8 w) (no change/≥25% decrease) | 0.999 (0.678, 1.474) | 0.998 | 1.132 (0.494, 2.594) | 0.770 | ||
| NLRc (3–6 m) (no change/≥25% increase/≥25% decrease) | 83/37/75 | 0.037 | 0.241 | |||
| NLRc (3–6 m) (no change/≥25% increase) | 1.640 (1.037, 2.594) | 0.034 | 1.596 (0.681, 3.744) | 0.282 | ||
| NLRc (3–6 m) (no change/≥25% decrease) | 0.902 (0.598, 1.361) | 0.623 | 0.708 (0.293, 1.709) | 0.442 | ||
BCLC, Barcelona clinic liver cancer; AFP, α-fetoprotein; NLR, neutrophil-to-lymphocyte ratio; Pre-NLR, preoperative NLR; NLRc, changes of NLR.